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Targeted Stakeholder Consultation
in the context of a Fitness Check of the EU legislation
with regard to Endocrine Disruptors
Factual Summary Report

PART 1.
Introduction
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Introduction
The European Commission is taking a cross-cutting look at the 
approach to the assessment and management of endocrine 
disruptors (EDs) in a broad range of legislation through what 
is described as a Fitness Check1. The goal is to analyse the 
coherence of the different approaches to this topic, identify 
possible gaps and synergies, and assess their collective impact 
on human health and the environment.
Stakeholder consultation is an essential step to collect evidence 
for any Fitness Check. It aims at gathering inputs from a broad 
range of stakeholder groups as well as citizens to ensure that 
relevant evidence and views from all interested parties are 
considered in the evaluation. This ED Fitness Check includes two 
open consultations, notably a public consultation (designed from a 
citizen’s perspective) and a stakeholder consultation (designed for 
stakeholders and experts). There is also a survey aimed to collect 
the views of micro, small and medium-sized enterprises (SMEs).
This factual summary report provides a brief factual overview of 
the open targeted stakeholder consultation, with information 
on the respondents as well as the number of responses and 
range of opinions.
The aims of the stakeholder consultation were:
• To collect views on possible lack of legislative coherence 
of EU legislation with respect to EDs and possible impacts on 
stakeholders;
• To collect information on the effectiveness of the current 
EU legislation for the identification and risk management of 
endocrine disruptors;
• To collect information on the efficiency of procedures for the 
identification and risk management of EDs (e.g. duplication of 
efforts) and to identify opportunities for improvement.
1 https://ec.europa.eu/info/law/better-regulation/have-your-say/
initiatives/2142-Fitness-Check-on-endocrine-disruptors
3
This document should be regarded solely as a summary of the contributions made by respondents to the 
targeted stakeholder consultation on the Fitness Check of the EU legislation on endocrine disruptors. It 
cannot in any circumstances be regarded as the official position of the European Commission or its services.
The survey was an open consultation posted on the European 
Commission’s endocrine disruptor webportal2 for a period of 8 
weeks from 06/12/2019 to 31/01/2020.
The questionnaire was structured into different parts. The first 
section concerned information about the respondents such as 
category of stakeholder, country of origin and residency, and 
regulatory sector of interest. The second section asked about 
the level of familiarity with the different pieces of legislation 
within the scope of the Fitness Check and then went on to ask 
questions, seeking views and information on different aspects 
of coherence, effectiveness, efficiency, relevance and EU-added 
value of the current approaches to identification, assessment 
and management of endocrine disruptors in the EU legislation.
Apart from the introductory section related to respondent 
characteristics, the survey did not include any mandatory field. 
It was therefore possible for respondents to leave one or more 
questions unanswered. As a result, the total number of responses 
to each question varied.
Some questions were aimed at specific categories of 
stakeholders: questions 25, 26 and 29 were intended for 
business associations, company/business organisations and 
public authorities; questions 27, 28 and 35 were intended for 
business associations and company/business organisations. 
These questions did not appear to respondents identifying 
themselves in other categories.
The survey consisted of both closed and open questions, 
including closed questions followed by an open field for 
explanation of the answer.
Overall 183 replies were received. A quality check of the 
responses evidenced a few replicates in the answers that will 
be taken into account during the final analysis. These replicate 
2 https://ec.europa.eu/info/policies/endocrine-disruptors_en
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answers, accounting for less than 15% of the total number of 
responses and being spread across the different stakeholders 
categories, are not expected to have a statistical impact on the 
numbers presented in this report.
This document reports the answers to the closed questions 
and provides an indication of the number of responses to the 
open questions. Responses to both closed and open questions 
will provide an essential input to the Fitness Check carried out 
by the European Commission. A more detailed analysis of the 
responses to the three consultations will be published in a 
synopsis report along with the Fitness Check evaluation at the 
end of the process.
PART 2.
Who responded to the survey
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Who responded to the survey
Replies provided to the survey cover all categories of respondents 
with respect to their stakeholder category:
• 47 come from Business associations
• 35 come from Public authorities
• 31 come from Company or business organisations
• 27 come from Civil society organisations
• 14 come from Academic/Research institutions
• 11 come from Trade unions
7
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The most represented country is Belgium with 48 respondents, 
followed by France (27), Germany (18) and Spain (11).
Answers Percentage
Belgium 48 26%
France 27 15%
Germany 18 10%
Spain 11 6%
Denmark 8 4%
Italy 7 4%
United Kingdom 6 3%
Sweden 5 3%
Austria 4 2%
Bulgaria 4 2%
Luxembourg 4 2%
Finland 3 2%
Hungary 3 2%
Ireland 3 2%
Portugal 3 2%
Latvia 2 1%
Netherlands 2 1%
Poland 2 1%
Romania 2 1%
Slovenia 2 1%
Croatia 1 1%
Cyprus 1 1%
Lithuania 1 1%
Malta 1 1%
Slovak Republic 1 1%
Other (Please specify) 13 7%
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Answers Percentage
General chemicals 51 14%
Biocidal products 43 12%
Cosmetics 40 11%
Plant Protection Products 33 9%
Food contact materials 30 8%
Detergents 28 8%
Food additives 25 7%
Medical devices 24 6%
Human and veterinary medicines 20 5%
Fertilisers 16 4%
Water industry 16 4%
Waste/recycling industry 16 4%
Electric and electronic equipment 15 4%
Toys 14 4%
Respondents outside of the EU are from Switzerland (6), USA (3), 
Norway (2), Japan (1) and Turkey (1).
Among economic operators (companies and business 
associations) and public authorities, the main sectors of interest 
are General Chemicals (14%), Biocidal Products (12%) and 
Cosmetics (11%).
9
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The geographical scope of the respondents is 61% international 
and 39% national, regional or local.
10
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The size of the respondents’ organisations is large for almost half 
of the respondents (48%), others being medium (20%), small 
(20%) or micro (19%). The Fitness Check also includes a survey 
of small and medium-sized enterprises (open from 1 February to 
9 March 2020) the outcome of which will be reported separately.
PART 3.
What did the respondents say?
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Very 
familiar
Fairly 
familiar
A little 
familiar
Not at all 
familiar
REACH Regulation (EC) 1907/2006 122 32 20 2
CLP: Classification, Labelling and Packaging 
of substances and mixtures (EC) 1272/2008
113 35 17 10
Biocidal Products Regulation (EU) 2012/528 60 57 42 13
Cosmetic Products Regulation (EC) 
1223/2009
59 35 35 40
Plant Protection Products Regulation (EC) 
1107/2009
51 41 42 38
How familiar are you with the following pieces of 
legislation?
The familiarity of the respondents with the pieces of EU 
legislation included in the scope of the Fitness Check is 
considered relevant to the interpretation of the replies provided 
to the other questions in the survey.
Among the listed legislative instruments, the respondents are 
most familiar with the following pieces of legislation:
Q 01
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Very 
familiar
Fairly 
familiar
A little 
familiar
Not at all 
familiar
Fertilisers Regulation (EC) 2003/2003 and 
Regulation (EU) 2019/1009
21 18 36 91
Medicinal Products for Humans Directive 
2001/83/EC
15 23 52 77
Marine Strategy Framework Directive 
2008/56/EC
15 16 48 85
Urban Waste Water Directive 91/271/EEC 21 9 44 90
Veterinary Medicinal Products Regulation 
(EU) 2019/6
16 14 40 97
In vitro Diagnostic Medical Devices 
Regulation (EU) 2017/746
14 12 45 94
The respondents are least familiar with the following legislative 
instruments:
The European Commission has published criteria for the 
identification of endocrine disruptors under both the Biocidal 
Products Regulation and the Plant Protection Products 
Regulation, which are very similar to each other and based on 
the WHO definition3. Other pieces of EU legislation related to 
human health and environmental protection from manufactured 
chemicals do not contain such criteria.
3 “An endocrine disruptor is an exogenous substance or mixture that alters 
function(s) of the endocrine system and consequently causes adverse 
health effects in an intact organism, or its progeny, or (sub) populations.”
Horizontal approach to the 
identification of endocrine disruptors
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To what extent does the absence of harmonised 
criteria pose a problem to a coherent approach 
for the identification of endocrine disruptors?
Ninety-three percent of the respondents consider that the 
absence of harmonised criteria poses a problem to the 
identification of endocrine disruptors across sectors.
The Regulation on Classification, Labelling and Packaging (CLP) 
of substances and mixtures and the Globally Harmonized System 
of Classification and Labelling of Chemicals (GHS) set rules for 
the classification and labelling of hazardous substances, based 
on their physical, health or environmental hazards.
Do you think that the lack of a hazard category 
covering endocrine disrupting properties in the 
CLP Regulation and/or GHS poses a problem for the 
coherent identification of endocrine disruptors?
Opinion is divided on this topic with roughly half of the respondents 
(53%) thinking that this is a problem for a coherent ED identification.
Q 02
Q 03
 Answers Percentage
Yes 94 53 %
No 83 47 %
 Answers Percentage
It is an important problem, leading to incoherent identification of 
endocrine disruptors across sectors
150 93 %
It is not a problem, the criteria should be sector specific 11 7 %
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 Answers Percentage
Yes 86 51 %
No 84 49 %
Do you think that the lack of a hazard category 
covering endocrine disrupting properties in the CLP 
Regulation and/or GHS poses a problem for the 
coherent risk management of endocrine disruptors?
On this topic, opinion is also divided with half of the respondents 
(51%) thinking that the lack of a hazard category is a problem 
for coherent risk management.
The CLP Regulation applies different approaches to categorise 
hazards depending on the endpoints, which may include aspects 
related to severity of effects or strength of evidence. Some 
stakeholders have suggested to classify endocrine disruptors 
in one of three categories based on the level of evidence: i.e. 
known, presumed or suspected.
Do you think that a category of suspected 
endocrine disruptor should be introduced?
With regard to the need of a category of suspected endocrine 
disruptors, opinion is again divided with a bit more than half of 
respondents (53%) being in favour of introducing a category for 
suspected endocrine disruptors.
Q 04
Q 05
 Answers Percentage
Yes 89 53 %
No 79 47 %
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Under some pieces of legislation, endocrine disruptors are 
regulated based on their hazardous properties, whereas under 
others they are regulated on the basis of risk.
Are you aware of any inconsistencies in the way 
chemicals are identified and controlled with 
regard to endocrine disrupting properties across 
regulated areas in the EU?
Seventy-three percent of respondents are aware of 
inconsistencies in the way endocrine disruptors are identified 
and controlled in the European Union.
In your opinion, how do hazard-based criteria for 
identifying endocrine disruptors in combination 
with a hazard-based approach to decision-making 
affect the following objectives?
A majority of respondents consider that the use of hazard-based 
criteria for identifying endocrine disruptors in combination with 
a hazard-based approach to decision making would affect (very) 
Rationale and consequences of 
different regulatory approaches
Q 06
 Answers Percentage
Yes 123 73 %
No 45 27 %
Q 07a
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Very 
positively
Positively
No 
effect
Negatively
Very 
negatively
Don’t 
know
Human health 
protection
60 33 5 24 34 15
Environmental 
protection
62 30 9 26 28 15
Competitiveness 
and innovation
33 16 10 21 46 45
Functioning of the 
internal market
34 9 19 29 23 56
positively4 human health protection (93) and environmental 
protection (92) compared with 58 and 54 who viewed these 
impacts (very) negatively5.
The effects on “competitiveness and innovation” and on the 
“functioning of the internal market” are viewed more negatively 
than positively, although higher numbers of respondents indicate 
“no effect” or “don’t know”.
In your opinion, how do hazard-based criteria for 
identifying endocrine disruptors in combination 
with a risk-based approach to decision-making 
affect the following objectives?
Of those respondents expressing an opinion, the majority view 
positively or very positively a risk-based approach to decision 
making in relation to human health and environmental protection.
4 Sum of respondents agreeing very positively or positively.
5 Sum of respondents agreeing very negatively or negatively.
Q 07b
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The effects on “competitiveness and innovation” and on the 
“functioning of the internal market” are also viewed more 
positively than negatively, although higher numbers of 
respondents indicate “no effect” or “don’t know”.
Chemicals are managed under different EU regulations 
according to their uses and the environmental media into 
which they are released during their life cycle (production, use, 
recycling/disposal).
Are you aware of any gaps or overlaps in the way 
endocrine disruptors are regulated in the EU?
Seventy-three percent of respondents consider that there are 
gaps or overlaps in the EU legislation on endocrine disruptors.
Very 
positively
Positively
No 
effect
Negatively
Very 
negatively
Don’t 
know
Human health 
protection
60 51 3 32 10 14
Environmental 
protection
60 49 4 33 10 13
Competitiveness 
and innovation
37 42 15 29 4 43
Functioning of the 
internal market
32 28 18 28 5 56
Q 08
 Answers Percentage
Yes 127 73 %
No 46 27 %
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Have you experienced issues or problems because 
endocrine disruptors are regulated differently in 
the EU compared with non-EU countries?
On this topic, opinion is divided with half of the respondents 
(51%) not experiencing issues or problems due to endocrine 
disruptors being regulated differently in the EU compared to 
non-EU countries.
Do you have further comments on the coherence 
of the EU legislation with regard to endocrine 
disruptors?
Ninety-four respondents provided answers to this open question. 
An analysis of the answers will be presented in the synopsis report.
Effectiveness in achieving policy 
objectives
A common goal of EU chemicals legislation is the protection 
of human and environmental health, by minimising exposure 
to hazardous chemicals, while at the same time improving the 
functioning of the internal market, enhancing competitiveness 
and innovation, and minimising animal testing. Some regulations 
have specific provisions for the identification and control of 
endocrine disruptors.
Q 09
 Answers Percentage
Yes 81 49 %
No 85 51 %
Q 10
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Do you agree with the following statements?
a) The regulatory process to identify and control substances 
with endocrine disrupting properties in Biocidal Products is 
effective in:
With regard to biocidal products, of those expressing an opinion 
there is a roughly even split between those that consider the 
regulation is effective in protecting human health and those that 
do not when considering consumers (51 agree6, 42 disagree7, and 
18 neither agree nor disagree), workers (46 agree, 43 disagree, 
and 19 neither agree nor disagree) or citizens exposed via the 
environment (43 agree, 47 disagree and 21 neither agree nor 
disagree). When it comes to protecting wildlife the number of 
6 Sum of respondents who strongly or moderately agree.
7 Sum of respondents who strongly or moderately disagree.
Q 11
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respondents agreeing that the regulation is effective decreases 
(35 agree, 50 disagree and 22 neither agree nor disagree).
Of those expressing an opinion, more respondents disagree than 
agree that the provisions related to EDs have a positive effect on 
the functioning of the internal market (19 agree, 28 disagree and 
34 neither agree nor disagree), on enhancing competitiveness 
and innovation (22 agree, 42 disagree and 27 neither agree nor 
disagree) and on promoting alternatives to animal testing (24 
agree, 40 disagree and 33 neither agree nor disagree). However, 
to these questions there are many respondents choosing “neither 
agree nor disagree” or “don’t know”.
b) The regulatory process to identify and control substances 
with endocrine disrupting properties in Plant Protection 
Products is effective in:
For plant protection products the pattern of responses is very 
similar to those given for biocidal products.
22
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c) The regulatory process to identify and control substances 
with endocrine disrupting properties under REACH is effective in:
With regard to the effectiveness of REACH in protecting human 
health and the environment there are fewer respondents 
selecting ‘neither agree nor disagree’ or choosing to select ‘don’t 
know’, than is the case for biocides or plant protection products.
Of those expressing an opinion there is a roughly even split 
between those that consider the regulation is effective in 
protecting human health and those that do not when considering 
consumers (57 agree, 62 disagree, and 17 neither agree nor 
disagree) or workers (56 agree, 59 disagree, and 18 neither 
agree nor disagree). A smaller proportion of respondents 
consider that the regulation is effective in protecting citizens 
exposed via the environment (46 agree, 63 disagree, and 26 
neither agree nor disagree) or wildlife (43 agree, 67 disagree, 
and 23 neither agree nor disagree).
23
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More respondents disagree than agree that the regulation (with 
respect to EDs) improves the functioning of the internal market 
(31 agree, 38 disagree, and 36 neither agree nor disagree) or 
enhances competitiveness and innovation (24 agree, 50 disagree, 
and 34 neither agree nor disagree) or promotes alternatives to 
animal testing (32 agree, 44 disagree, and 38 neither agree nor 
disagree). Again there are many respondents choosing “neither 
agree nor disagree” or “don’t know” to this group of questions.
d) The regulatory process to identify and control substances 
with endocrine disrupting properties in Cosmetics is effective in:
For cosmetics, more respondents disagree than agree that the 
regulation with respect to EDs is protecting consumer health (31 
agree, 48 disagree, and 23 neither agree nor disagree) or worker 
health (24 agree, 49 disagree, and 28 neither agree nor disagree).
Few respondents agree that it is improving the functioning of 
the internal market (13 agree, 31 disagree, and 44 neither agree 
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nor disagree) or enhancing competitiveness and innovation (15 
agree, 30 disagree, and 37 neither agree nor disagree). However 
the agree to disagree ratio changes around with respect to 
promoting alternatives to animal testing, where 34 moderately 
or strongly agree compared with 12 that strongly or moderately 
disagree. The number that “don’t know” or “neither agree nor 
disagree” is rather high.
e) The regulatory process to identify and control substances 
with endocrine disrupting properties in Medical Devices is 
effective in:
For medical devices, a large proportion of respondents say they 
do not know about the effectiveness of the regulatory process 
(ranging from 59 to 73). Of those expressing an opinion, more 
respondents disagree than agree that it is protecting consumers 
(25 agree, 35 disagree, and 15 neither agree nor disagree), 
protecting workers (23 agree, 29 disagree, and 19 neither agree 
nor disagree) or enhancing competitiveness and innovation (13 
agree, 29 disagree, and 23 neither agree nor disagree).
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More respondents neither agree nor disagree that it is improving 
the functioning of the internal market (9 agree, 21 disagree, 
and 31 neither agree nor disagree) or promoting alternatives to 
animal testing (11 agree, 11 disagree, and 39 neither agree nor 
disagree) compared with those that agree or disagree.
f) The regulatory process to control substances with endocrine 
disrupting properties under the Water Framework Directive is 
effective in:
Regarding the Water Framework Directive, more respondents 
disagree than agree that the directive is effective in minimising 
the exposure of citizens (22 agree, 47 disagree, and 12 neither 
agree nor disagree) or wildlife (27 agree, 47 disagree, and 
12 neither agree nor disagree) to endocrine disruptors via 
the environment. However, the numbers of “don’t knows” are 
relatively high.
26
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Aggregate exposure and combined 
effects
Humans and wildlife can be exposed to the same endocrine 
disruptor via various sources (aggregate exposure) if this 
substance is present in different types of products. Humans 
and wildlife can also be exposed to a combination of multiple 
endocrine disruptors from one or multiple sources, which may 
lead to combined effects (mixture/cocktail effect). Such effects 
may include additive and synergistic effects.
Aggregate exposure to one substance from 
all exposure sources — Do you agree with the 
following statements?
More respondents disagree than agree that the current regulatory 
framework protects humans (60 agree, 96 disagree, and 6 
neither agree nor disagree) or wildlife (39 agree, 92 disagree, 
and 14 neither agree nor disagree) from the risks associated 
with the aggregate exposure to one substance with endocrine 
disrupting properties from all exposure sources.
Q 12
Strongly 
agree
Moderately 
agree
Neither 
agree nor 
disagree
Moderately 
disagree
Strongly 
disagree
Don’t 
know
Humans are 
protected by the 
current regulatory 
framework 
25 35 6 33 63 8
Wildlife is 
protected by the 
current regulatory 
framework
19 20 14 23 69 24
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Combined exposure to multiple substances from 
all sources — Do you agree with the following 
statements?
Compared with Q12, a larger proportion of respondents disagree 
that the current regulatory framework protects humans (46 
agree, 100 disagree, and 14 neither agree nor disagree) or 
wildlife (27 agree, 95 disagree, and 23 neither agree nor 
disagree) from the risks associated with the combined exposure 
to different substances with endocrine disrupting properties 
(combined effects).
Vulnerable groups
The endocrine system controls a large number of processes in 
the body throughout life from early stages such as embryonic 
development, to later ones such as puberty, reproductive life 
and old age. It controls formation and functions of tissues and 
organs, as well as homeostasis of physiological processes.
Q 13
Strongly 
agree
Moderately 
agree
Neither 
agree nor 
disagree
Moderately 
disagree
Strongly 
disagree
Don’t 
know
Humans are 
protected by 
the current 
regulatory 
framework
14 32 14 24 76 9
Wildlife is 
protected by 
the current 
regulatory 
framework
9 18 23 15 80 21
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Do you think that the following groups are 
sufficiently protected from exposure to substances 
with endocrine disrupting properties?
For all population categories, the level of protection is regarded 
as insufficient by about two thirds of respondents (ranging 
between 56%8 for adults in general to 66% for the unborn 
exposed during pregnancy).
8 Percentage of “No” answers, excluding respondents who don’t know.
Q 14
Yes No Don’t know
unborn through exposure during 
pregnancy
47 90 34
newborn up to the age of 3 49 90 30
children until puberty 49 90 30
young persons around the age of 
puberty
48 91 30
pregnant women 52 87 29
adults in general 63 80 26
people at work 54 85 30
elderly 56 78 34
people with illnesses 46 81 43
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Data requirements and available 
regulatory test methods
Several EU regulations require registrants or applicants to 
perform some tests on the toxicity of their substance. These 
tests should be run according to validated test methods that 
are accepted by the authorities (Test Guidelines adopted at 
international level such as the OECD, or methods laid down in the 
Commission Regulation (EC) 440/2008 on test methods). Several 
of these tests can be used to identify endocrine disruptors.
Are available regulatory tests sufficient to identify 
endocrine disruptors for humans (including 
vulnerable groups) as well as wildlife?
A majority of respondents (74%) consider the available 
regulatory tests insufficient to identify EDs.
 Answers Percentage
Yes 41 26 %
No 116 74 %
Q 15
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Are current provisions for data requirements 
laid down in relevant legislation (REACH, Biocidal 
Products Regulation, Plant Protection Products 
Regulation) sufficient to identify endocrine 
disruptors for humans (including vulnerable 
groups) as well as wildlife?
Similarly, a majority of respondents (71%) consider that the 
data requirements laid down in relevant legislation (REACH, 
Biocidal Products Regulation, Plant Protection Products 
Regulation) are insufficient.
Considering the information requirements of 
REACH, the Biocidal Products Regulation and 
the Plant Protection Products Regulation, do you 
think the likelihood of identifying a substance 
as an endocrine disruptor is lower under one of 
these regulations compared to the others?
The likelihood to identify an endocrine disruptor under REACH, the 
Biocidal Products Regulation and the Plant Protection Products 
Regulation is about the same, according to 53% of respondents.
Q 16
 Answers Percentage
Yes 46 29 %
No 114 71 %
Q 17
 Answers Percentage
Yes 65 47 %
No 74 53 %
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Do you have any further comments on available 
regulatory test methods and data requirements 
under REACH, the Biocidal Products Regulation, 
the Plant Protection Products Regulation, and 
other sector specific legislation?
Sixty-three respondents answered to this open question. An 
analysis of the answers will be presented in the synopsis report.
Regulatory testing and animal 
welfare
Data generation according to standard information requirements 
is expensive, time consuming and requires the use of animals. 
The recently adopted criteria for identifying endocrine disruptors 
require information on endocrine activity and adverse effects.
Do you agree with the following statement? 
In vitro and/or in silico methods are not used 
systematically enough to prioritise further 
investigations.
Among those who expressed an opinion, a majority of 
respondents think that in vitro and/or in silico methods are not 
used systematically enough to prioritise further investigations 
(80 agree, 7 disagree, and 38 neither agree nor disagree).
Q 18
Q 19
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Regulations requiring testing for endocrine disrupting properties of 
a substance (Biocidal Products Regulation, Plant Protection Products 
Regulation, REACH) specifically require the use of vertebrate 
animals to be minimised, in accordance with Directive 2010/63/EU 
on the protection of animals used for scientific purposes.
In your opinion, is the impact of assessing 
chemicals for endocrine disrupting properties on 
animal welfare minimised in the EU?
A bit more than half of the respondents expressing an opinion 
(54%) think that the impact of assessing chemicals for endocrine 
disrupting properties on animal welfare is minimised in the EU to 
the extent possible.
 Answers
Strongly agree 39
Moderately agree 41
Neither agree nor disagree 38
Moderately disagree 5
Strongly disagree 2
Don’t know 41
Q 20
Answers
Not at all 12
Insufficiently minimised 43
Minimised to the extent possible 64
Don’t know 51
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Do you have recommendations on how to further 
minimise the impact of assessing chemicals for 
endocrine disrupting properties on animal welfare?
One hundred and eight respondents answered to this open 
question. An analysis of the answers will be presented in the 
synopsis report.
Effectiveness of regulatory 
procedures
The following sectors are regulated via sector-specific legislation 
as well as by horizontal/other legislation (e.g. REACH, Biocidal 
Products Regulation, CLP Regulation).
Are you aware of issues that result from the lack 
of specific provisions for identifying endocrine 
disruptors in sector-specific legislation for the 
following areas:
A majority of respondents are not aware of issues resulting from 
the lack of specific provisions for identifying endocrine disruptors 
in sector-specific legislation (from 60% to 70%).
Q 21
Q 22
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Are you aware of issues that result from the lack 
of specific provisions for managing endocrine 
disruptors in sector-specific legislation for the 
following areas:
For all categories, between 60 and 70% of respondents are not 
aware of issues resulting from the lack of specific provisions for 
managing endocrine disruptors in sector-specific legislation.
Q 23
Yes No
Human and veterinary pharmaceuticals (only for 
effects on the environment)
39 80
Electrical and electronic equipment 40 81
Other (please specify) 33 65
Medical devices and in vitro diagnostic medical 
devices (only for effects on the environment)
42 81
Waste/recycling 42 81
Food additives 43 78
Toys 45 77
Workers protection 47 78
Detergents 46 75
Fertilisers 46 74
Cosmetics 52 83
Food contact materials 52 79
Water 51 77
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In your view, on which areas should market 
surveillance authorities focus their activities to 
effectively enforce chemical safety of products 
as regards endocrine disruptors?
A majority of respondents (80 to 90% of those who expressed 
an opinion) indicated that authorities should focus on market 
surveillance across all sectors listed.
Yes No
Electrical and electronic equipment 39 81
Food additives 40 80
Fertilisers 41 79
Human and veterinary pharmaceuticals 
(only for effects on the environment)
41 79
Medical devices and in vitro diagnostic 
medical devices (only for effects on the 
environment)
43 82
Waste/recycling 42 78
Detergents 44 76
Workers protection 45 77
Toys 45 75
Water 49 76
Cosmetics 53 81
Food contact materials 51 76
Other (please specify) 32 72
Q 24
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Efficiency of regulatory provisions 
for endocrine disruptors
Benefits of regulatory intervention include human health and 
environmental protection, smooth functioning of the internal 
market, innovation and competitiveness. Costs can be economic 
Yes No
Don’t 
know
Toys 88 10 44
Food contact materials 99 12 37
General chemicals 93 13 40
Cosmetics 92 13 37
Human and veterinary pharmaceuticals 
(only for effects on the environment)
75 11 52
Food additives 90 14 40
Waste/recycling 80 13 50
Plant Protection Products 87 16 39
Fertilisers 74 14 49
Biocidal products 88 17 38
Detergents 76 16 48
Medical devices and in vitro diagnostic 
medical devices (only for effects on the 
environment)
71 15 53
Electrical and electronic equipment 65 15 61
Other (please specify) 27 13 63
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(time, resources) as well as ethical (e.g. use of laboratory animals 
for testing). Efficiency considers the benefits in relation to costs.
Has the implementation of regulatory 
requirements for endocrine disruptors increased 
your total operating costs?
Eighty-eight percent of the concerned respondents report 
an increase of costs related to regulatory requirements for 
endocrine disruptors. Forty-eight percent consider the increased 
costs to be significant.
Has the assessment of substances for endocrine 
disrupting properties delayed your assessment 
work in other areas of human health or 
environmental protection?
Of those respondents to whom the question is applicabile, about 
80% reported a delay in their assessment work in other areas 
of human health or environmental protection. Half of these 
reported the delay to be significant.
Q 25
Q 26
 Answers
Yes, to a significant extent 29
Yes, but not to a significant extent 24
No 7
Not applicable 42
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What is the cost increase for your company 
(companies your association is representing) to 
comply with the regulatory requirements (e.g. 
testing, restriction or ban) specifically related to 
endocrine disruptors?
Few respondents replied to this question. The type of costs incurring 
the highest cost increase was most commonly reported to be related 
to the provision of test data on endocrine disrupting properties.
Q 27
 Answers
Yes, to a significant extent 24
Yes, but not to a significant extent 27
No 13
Not applicable 40
More 
than 
10%
Between 
5 and 
10%
Between 
1 and 5%
Below 
1%
Don’t 
know
Not 
applicable
Costs related to the provision of 
test data on endocrine disrupting 
properties
14 2 4 1 27 20
Cost to replace substances due 
to endocrine disrupting properties 
(e.g. as a producer or user)
7 4 7 1 27 19
Investment in the development 
of new testing methodologies for 
endocrine disrupting properties
6 8 3 0 25 26
Costs related to the preparation 
of registration or authorisation 
dossiers covering endocrine 
disrupting properties
5 7 6 4 22 24
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What has been the impact of the provisions for 
endocrine disruptors on the sector you represent?
More of the respondents expressing an opinion report the impact 
to be negative rather than positive, impacting productivity (0 
positively, 22 (very) negatively, and 9 no impact), profitability 
(1 very positively, 28 (very) negatively, and 3 no impact) and 
international trade (1 very positively, 25 (very) negatively, and 6 
no impact) and to a lesser extent innovation (6 (very) positively, 
22 (very) negatively, and 14 no impact).
Q 28
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Are the costs of the provisions for endocrine 
disruptor identification and management, 
for the sector(s) you operate in, justified and 
proportionate to the benefits accrued for society 
and the environment?
Of those respondents expressing an opinion, 79% consider the 
costs for endocrine disruptor identification and management 
to be to some extent or fully justified and proportionate to the 
benefits accrued for society and the environment in their sectors.
Adequacy of the legislation to 
address needs and concerns on 
endocrine disruptors
In 1999 the European Commission published a Community 
Strategy on endocrine disruptors9, reflecting public concerns that 
these substances might cause diseases/disorders in humans and 
affect wildlife populations and biodiversity. Diseases/disorders in 
humans that are endocrine-related (i.e. via effect on the endocrine 
9 h t t p s : / / e u r - l e x . e u r o p a . e u / l e g a l - c o n t e n t / E N /
TXT/?uri=COM:1999:0706:FIN
Q 29
 Answers
Not at all 12
To some extent 28
Fully 17
Don’t know 40
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system) might result from a combination of factors such as 
genetic origin, diet, lifestyle, exposure to endocrine disruptors 
and other chemical stressors. Effects on wildlife populations and 
biodiversity might be caused by a combination of factors such 
as habitat loss, climate change, exposure to endocrine disruptors 
and other chemical stressors.
To what extent do you think exposure to endocrine 
disruptors is contributing to the increase in 
endocrine-related human diseases/disorders, in 
the EU, in comparison with other factors?
Sixty-two percent of respondents who expressed an opinion 
think that exposure to endocrine disruptors is contributing to a 
significant extent to the increase in endocrine-related human 
diseases/disorders in the EU, in comparison with other factors.
To what extent do you think exposure to endocrine 
disruptors is contributing to the decrease in 
aquatic and terrestrial biodiversity in the EU, in 
comparison with other factors?
Sixty-four percent of respondents who expressed an opinion 
think that endocrine disruptors are contributing to a significant 
Q 30
Q 31
 Answers
To a significant extent 75
Not to a significant extent 40
Not at all 6
Don’t know 46
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extent to the decrease in aquatic and terrestrial biodiversity in 
the EU, in comparison with other factors. However, a relatively 
large number of respondents selected ‘don’t know’
The 1999 Community Strategy highlighted the need for research 
and development of new tools to understand the mechanisms of 
endocrine disruption.
Is the regulatory framework flexible enough 
to take into account new scientific information 
and methods in the assessment of endocrine 
disrupting properties (e.g. new toxicological tests, 
(bio)monitoring data, (eco)epidemiology)?
Fifty-three percent of respondents think that the regulatory 
framework is not flexible enough to take into account new 
scientific information and methods in the assessment of 
endocrine disrupting properties.
 Answers
To a significant extent 70
Not to a significant extent 36
Not at all 3
Don’t know 57
Q 32
 Answers
Yes 73
No 84
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Do you have any further comments on the 
adequacy of legislation to address societal needs 
and concerns on endocrine disruptors?
Sixty-four respondents answered to this open question. An 
analysis of the answers will be presented in the synopsis report.
Added value of EU level 
intervention
There have been instances where Member State authorities 
have taken unilateral action on endocrine disruptors before a 
decision has been taken at the EU level. For example, in October 
2012, the French authorities introduced a ban of Bisphenol A in 
all Food Contact Materials, applicable from July 2015.
With regard to unilateral action on endocrine 
disruptors by Member States Authorities, do you 
think this is justifiable?
Thirty-two percent of the respondents think it is not justifiable 
at all. Another thirty-two percent think it is justifiable but should 
be followed by an EU wide action. Twenty-four percent think that 
this is justifiable in some cases, while 2% consider EDs should 
not be regulated at EU level.
Q 33
Q 34
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Has your organisation been impacted by unilateral 
actions at national level?
Of those who answered, 48% of respondents consider that 
their organisations have been impacted by unilateral actions at 
national level.
Do you have any further comments on the added 
value of regulating endocrine disruptors at EU 
level?
Seventy-eight respondents answered to this open question. An 
analysis of the answers will be presented in the synopsis report.
 Answers
This is not justifiable – decisions should be taken at EU level and 
all citizens of the EU should be protected in an equal way, while 
preserving the integrity of the single market.
59
This is justifiable, but it should be followed by an EU wide action to 
preserve the integrity of the single market.
59
This is justifiable in some cases – protection of human health or 
the environment is more important than preserving the integrity of 
the single market.
44
This is justifiable – endocrine disruptors should not be regulated at 
EU level.
4
Q 35
 Answers
Yes 30
No 33
Q 36
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